Cargando…

Clinical Outcomes of the Oral Suspension vs Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections

BACKGROUND: Posaconazole is effective prophylaxis for invasive fungal infections (IFIs). We compared incidence of breakthrough IFI (bIFI) and early posaconazole discontinuation between patients receiving delayed-release tablet and oral suspension formulations. METHODS: This was a retrospective cohor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tallman, Gregory B, Furuno, Jon P, Noble, Brie N, Bubalo, Joseph S, Forrest, Graeme N, Lewis, James S, Bienvenida, Ana F, Holmes, Courtney A, Weber, Bo R, McGregor, Jessina C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631689/ http://dx.doi.org/10.1093/ofid/ofx163.039

Ejemplares similares

Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections
por: Furuno, Jon P., et al.
Publicado: (2018)

Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies
por: Leclerc, Elisabeth, et al.
Publicado: (2018)

Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation
por: Belling, Morgan, et al.
Publicado: (2017)

Incidence and Outcomes of Cytomegalovirus (CMV) Infection among Hematopoietic Stem Cell Transplant (HSCT) Recipients
por: Furuno, Jon P, et al.
Publicado: (2017)

1469 Posaconazole salvage treatment for invasive fungal infection : a single center experience with utilization of posaconazole oral suspension or delayed-released tablet
por: Kim, Jong Hun, et al.
Publicado: (2014)

874 Risk Factors for Complicated Urinary Tract Infection (cUTI) due to Pseudomonas
por: Mcgregor, Jessina C., et al.
Publicado: (2014)

941. Isavuconazole Prophylaxis Against Invasive Fungal Infection: A Pooled Analysis with a Comparison of Posaconazole Delayed-release Tablet Prophylaxis
por: Lee, Chaeryoung, et al.
Publicado: (2021)

Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease
por: Cornely, Oliver A., et al.
Publicado: (2016)

Comparison of Plasma Concentrations of Posaconazole with the Oral Suspension and Tablet in Korean Patients with Hematologic Malignancies
por: Suh, Hyeon Jeong, et al.
Publicado: (2017)

Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections
por: Wiederhold, Nathan P
Publicado: (2015)

492 Complicated Intra-abdominal Infection (cIAI) and 30-day Hospital Readmission
por: Furuno, Jon P., et al.
Publicado: (2014)

2051. Frequency of Inappropriate Antibiotic Prescribing in Nursing Homes
por: Kanchagar, Chitra, et al.
Publicado: (2019)

200. Frequency and Characteristics of Patients Switched from Intravenous to Oral Antibiotic Therapy on Discharge to Nursing Homes
por: Colangeli, Hailey N, et al.
Publicado: (2020)

63. Frequency and Outcomes of Patients Prescribed Antibiotics for Extended Durations on Discharge from the Hospital to Nursing Homes
por: Molina, Kaitlyn E, et al.
Publicado: (2020)

201. Healthcare utilization outcomes of patients prescribed fluoroquinolones on discharge from the hospital to nursing homes
por: Lantz, Tyler L, et al.
Publicado: (2020)

General Perceptions and Knowledge of Antibiotic Resistance and Antibiotic Use Behavior: A Cross-Sectional Survey of US Adults
por: McCracken, Caitlin M., et al.
Publicado: (2023)

Posaconazole oral suspension for secondary antifungal prophylaxis in allogeneic stem cell transplantation recipients: a retrospective study
por: Ye, Peipei, et al.
Publicado: (2022)

413. Intravenous and Tablet Formulation of Posaconazole in Antifungal Therapy and Prophylaxis: A Retrospective, Non-Interventional, Multicenter Analysis of Patients Treated in German Tertiary-Care Hospitals
por: Heimann, Sebastian M, et al.
Publicado: (2018)

2054. Hospital-initiated Antibiotics in Nursing Homes
por: Furuno, Jon P, et al.
Publicado: (2019)

2053. Information Gaps Among Patients Prescribed Antibiotics on Discharge to Nursing Homes
por: Furuno, Jon P, et al.
Publicado: (2019)

755. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies
por: Almutairy, Reem F, et al.
Publicado: (2020)

Impact of Culturing All Uncomplicated Urinary Tract Infections on the Estimated Prevalence Of Resistance in the Primary Care Setting
por: Tallman, Gregory B, et al.
Publicado: (2017)

1558. A Population Pharmacokinetic Model for Posaconazole Intravenous Solution and Oral Powder for Suspension Formulations in Pediatric Patients With Neutropenia
por: Winchell, Gregory A, et al.
Publicado: (2019)

Posaconazole in the management of refractory invasive fungal infections
por: Langner, Stefan, et al.
Publicado: (2008)

Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain
por: Cámara, Rafael, et al.
Publicado: (2017)

Role of New Antifungal Agents in the Treatment of Invasive Fungal Infections in Transplant Recipients: Isavuconazole and New Posaconazole Formulations
por: Li, Julius, et al.
Publicado: (2015)

Primary or Secondary Prophylaxis with Voriconazole Compared with Posaconazole for Prevention of Invasive Fungal Infections After Hematopoietic Stem Cell Transplantation
por: Jansen, Jeffrey W, et al.
Publicado: (2017)

Efficacy of Posaconazole Prophylaxis for Fungal Disease in Hematology Patients Treated With Chemotherapy and Transplantation: An Open-Label, Prospective, Observational Study
por: Li, Weiyang, et al.
Publicado: (2020)

2736. Real-world Effectiveness of Posaconazole Prophylaxis in Preventing Invasive Fungal Infections in Recipients of Allogeneic Stem Cell Transplantation
por: Álvarez-Ortega, Carolina, et al.
Publicado: (2023)

Clinical pharmacokinetics and dose recommendations for posaconazole gastroresistant tablets in children with cystic fibrosis
por: Bentley, Siân, et al.
Publicado: (2021)

Real-world assessment of the effectiveness of posaconazole for the prophylaxis and treatment of invasive fungal infections in hematological patients: A retrospective observational study
por: Chen, Xiaochen, et al.
Publicado: (2021)

Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin - review of the literature
por: Karthaus, M
Publicado: (2011)

Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia
por: Döring, M., et al.
Publicado: (2015)

Sample Preparation of Posaconazole Oral Suspensions for Identification of the Crystal Form of the Active Pharmaceutical Ingredient
por: Lykouras, Michail, et al.
Publicado: (2020)

Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection
por: Allegra, Sarah, et al.
Publicado: (2017)

2546. Administration of Crushed Posaconazole Delayed Release Tablets Failed to Achieve Therapeutic Levels
por: Kane, Nicholas, et al.
Publicado: (2023)

Cost Analysis of the Use of Voriconazole, Posaconazole and Micafungin in the Primary Prophylaxis of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Stem Cell Transplants
por: Grau, Santiago, et al.
Publicado: (2015)

Fatal Breakthrough Mucormycosis in an Acute Myelogenous Leukemia Patient while on Posaconazole Prophylaxis
por: Kang, Seung Hun, et al.
Publicado: (2015)

Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma
por: Stemler, Jannik, et al.
Publicado: (2020)

Effectiveness of Posaconazole in Recalcitrant Fungal Keratitis Resistant to Conventional Antifungal Drugs
por: Altun, A., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mt7gdntpsee37h22ls17qcvh0r